Bavarian Nordic Expands Chikungunya Vaccine Reach with Brazil Deal
Event summary
- Bavarian Nordic partners with Eurofarma for exclusive distribution of its chikungunya vaccine in Brazil.
- Eurofarma gains right of first refusal for Latin American expansion.
- Regulatory submission in Brazil expected in H1 2026, with potential launch in H2 2027.
- Deal is transfer price and royalty-based with no upfront or milestone payments.
- Brazil accounts for half of global chikungunya cases and deaths.
The big picture
This partnership marks Bavarian Nordic's first entry into Latin America for its chikungunya vaccine, addressing a critical public health need in Brazil. The deal follows successful Western market launches in 2025 and positions the company to potentially expand its footprint across the region. With chikungunya cases severely underreported and often misdiagnosed, this distribution agreement could significantly improve disease prevention in endemic populations.
What we're watching
- Regulatory Timing
- Whether Anvisa approval will meet the H1 2026 target and enable a 2027 launch.
- Market Penetration
- The pace at which Eurofarma can establish the vaccine in Brazil's under-served chikungunya market.
- Geographic Expansion
- How quickly Bavarian Nordic can leverage this deal to expand into other Latin American markets.
Related topics